Alport syndrome
ICD-10 Q87.8 · ICD-11 LD2H.Y

Treatment of X-linked Alport Syndrome in Males

Male patients with X-linked Alport syndrome face a progressive risk of renal failure that requires proactive, lifelong nephrology management. Optimising modifiable risk factors is central to slowing disease progression.

Clinical scenario

Male patient with X-linked Alport syndrome. Risk factors for progressive renal failure — including hypertension, proteinuria, and dyslipidemia — require careful, sustained management throughout the patient's care.

Treatment approach

The protocol specifies a pharmacological intervention that may be initiated early — even before certain clinical markers develop — particularly in patients with relevant genetic mutations or a family history suggesting early-onset renal failure. The complete regimen, accompanying measures, and sequencing are available in the full protocol.

Primary clinical goal

Reduction in proteinuria.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1681/ASN.2012020148

Males with X-linked Alport syndrome should be managed lifelong by a nephrologist and have their risk factors for progressive renal failure optimized, including careful management of hypertension, proteinuria, and dyslipidemia.

Treatment with ACE inhibitors, even before the onset of proteinuria, especially in individuals with genetic mutations or a family history consistent with early-onset renal failure, may delay the onset of end-stage disease and improve life expectancy.

Angiotensin-converting enzyme (ACE) inhibitors reduce proteinuria in children with X-linked Alport syndrome.

View source ↗